The Investor
05 May 2026, 09:22
Vertex Pharmaceuticals Slips 1% in Pre-Market After Solid Q1 Results
May 5, 2026
Vertex Pharmaceuticals (Nasdaq: VRTX) edged lower by about 1% in Tuesday's pre-market session following the release of its first quarter 2026 earnings report after Monday's close. The modest decline appears to reflect a market that found the results solid but not surprising — a steady, well-managed business delivering in line with expectations rather than a dramatic beat.
Q1 by the Numbers
Total revenue came in at $2.99 billion, an 8% increase compared to the first quarter of 2025. Growth was driven by the continued strength of the company's cystic fibrosis portfolio alongside a meaningful contribution from newer products. In the U.S., revenue rose 7% to $1.78 billion, supported by strong demand for ALYFTREK, higher net prices across CF therapies, and early contributions from CASGEVY and JOURNAVX. Outside the U.S., revenue grew 9% to $1.21 billion, helped in part by favorable foreign exchange movements.
CEO Reshma Kewalramani highlighted that CASGEVY and JOURNAVX together accounted for more than 25% of the company's quarterly growth, calling it a sign of a revenue base that is becoming increasingly diversified beyond cystic fibrosis.
GAAP net income for the quarter was $1.0 billion, up sharply from $646 million in the same period a year ago — though that comparison is flattered by a $379 million intangible asset impairment charge that weighed on Q1 2025 results. Non-GAAP net income came in at $1.1 billion, up $93 million year-over-year. Cash and marketable securities grew to $13.0 billion as of March 31, compared to $12.3 billion at the end of 2025.
Guidance Unchanged
Vertex reiterated its full year 2026 financial guidance without revision, targeting total revenue of $12.95 billion to $13.1 billion. Non-CF product revenue is expected to reach at least $500 million. The company maintained its combined non-GAAP R&D and SG&A expense guidance of $5.65 to $5.75 billion and a non-GAAP effective tax rate of 19.5% to 20.5%.
The unchanged guidance may be one reason the stock is seeing mild selling pressure. In a market that rewards upward revisions, reiterating prior forecasts — even strong ones — can read as a lack of near-term catalysts.
Pipeline Progress
On the pipeline front, Vertex completed a rolling BLA submission for povetacicept, seeking U.S. accelerated approval in IgA nephropathy following positive Phase 3 interim data. The company also initiated a Phase 3 study in primary membranous nephropathy and a Phase 2 study in generalized myasthenia gravis — moves that signal the company is serious about building a fourth franchise in nephrology alongside CF, gene therapy, and pain.
The FDA recently approved label extensions for both ALYFTREK and TRIKAFTA, making approximately 800 more CF patients in the U.S. eligible for treatment for the first time. Additionally, Vertex submitted for U.S. approval of CASGEVY in children ages 5 to 11 with sickle cell disease or transfusion-dependent beta thalassemia, receiving a Commissioner's National Priority Voucher indicating an accelerated review timeline.
JOURNAVX, the company's first-in-class non-opioid pain medication launched in March 2025, surpassed one million total prescriptions filled, with more than 350,000 filled in Q1 alone. Vertex recorded $29 million in JOURNAVX revenue for the quarter and recently secured Medicare Part D coverage adding approximately 10 million lives.
The Bigger Picture
Vertex is not a company in crisis — far from it. It has a dominant position in cystic fibrosis, a growing gene therapy business, and a pain franchise gaining meaningful traction. The mild pre-market dip likely reflects the absence of a positive guidance revision rather than any fundamental concern. For long-term investors, the pipeline news — particularly around povetacicept in nephrology — may prove to be the most significant takeaway from the quarter.
May 5, 2026
Vertex Pharmaceuticals (Nasdaq: VRTX) edged lower by about 1% in Tuesday's pre-market session following the release of its first quarter 2026 earnings report after Monday's close. The modest decline appears to reflect a market that found the results solid but not surprising — a steady, well-managed business delivering in line with expectations rather than a dramatic beat.
Q1 by the Numbers
Total revenue came in at $2.99 billion, an 8% increase compared to the first quarter of 2025. Growth was driven by the continued strength of the company's cystic fibrosis portfolio alongside a meaningful contribution from newer products. In the U.S., revenue rose 7% to $1.78 billion, supported by strong demand for ALYFTREK, higher net prices across CF therapies, and early contributions from CASGEVY and JOURNAVX. Outside the U.S., revenue grew 9% to $1.21 billion, helped in part by favorable foreign exchange movements.
CEO Reshma Kewalramani highlighted that CASGEVY and JOURNAVX together accounted for more than 25% of the company's quarterly growth, calling it a sign of a revenue base that is becoming increasingly diversified beyond cystic fibrosis.
GAAP net income for the quarter was $1.0 billion, up sharply from $646 million in the same period a year ago — though that comparison is flattered by a $379 million intangible asset impairment charge that weighed on Q1 2025 results. Non-GAAP net income came in at $1.1 billion, up $93 million year-over-year. Cash and marketable securities grew to $13.0 billion as of March 31, compared to $12.3 billion at the end of 2025.
Guidance Unchanged
Vertex reiterated its full year 2026 financial guidance without revision, targeting total revenue of $12.95 billion to $13.1 billion. Non-CF product revenue is expected to reach at least $500 million. The company maintained its combined non-GAAP R&D and SG&A expense guidance of $5.65 to $5.75 billion and a non-GAAP effective tax rate of 19.5% to 20.5%.
The unchanged guidance may be one reason the stock is seeing mild selling pressure. In a market that rewards upward revisions, reiterating prior forecasts — even strong ones — can read as a lack of near-term catalysts.
Pipeline Progress
On the pipeline front, Vertex completed a rolling BLA submission for povetacicept, seeking U.S. accelerated approval in IgA nephropathy following positive Phase 3 interim data. The company also initiated a Phase 3 study in primary membranous nephropathy and a Phase 2 study in generalized myasthenia gravis — moves that signal the company is serious about building a fourth franchise in nephrology alongside CF, gene therapy, and pain.
The FDA recently approved label extensions for both ALYFTREK and TRIKAFTA, making approximately 800 more CF patients in the U.S. eligible for treatment for the first time. Additionally, Vertex submitted for U.S. approval of CASGEVY in children ages 5 to 11 with sickle cell disease or transfusion-dependent beta thalassemia, receiving a Commissioner's National Priority Voucher indicating an accelerated review timeline.
JOURNAVX, the company's first-in-class non-opioid pain medication launched in March 2025, surpassed one million total prescriptions filled, with more than 350,000 filled in Q1 alone. Vertex recorded $29 million in JOURNAVX revenue for the quarter and recently secured Medicare Part D coverage adding approximately 10 million lives.
The Bigger Picture
Vertex is not a company in crisis — far from it. It has a dominant position in cystic fibrosis, a growing gene therapy business, and a pain franchise gaining meaningful traction. The mild pre-market dip likely reflects the absence of a positive guidance revision rather than any fundamental concern. For long-term investors, the pipeline news — particularly around povetacicept in nephrology — may prove to be the most significant takeaway from the quarter.
